{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:01:19Z","timestamp":1791918079804,"version":"4.3.4"},"reference-count":225,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.humpath.2025.105826","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T11:08:22Z","timestamp":1749035302000},"page":"105826","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Genetic landscapes of breast tumors by next-generation sequencing with focus on less common types and genotype-phenotype correlations"],"prefix":"10.1016","volume":"162","author":[{"given":"Raza S.","family":"Hoda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5285-0862","authenticated-orcid":false,"given":"Gregor","family":"Krings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7403","key":"10.1016\/j.humpath.2025.105826_bib1","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nature11154","article-title":"Sequence analysis of mutations and translocations across breast cancer subtypes","volume":"486","author":"Banerji","year":"2012","journal-title":"Nature"},{"issue":"7418","key":"10.1016\/j.humpath.2025.105826_bib2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","author":"Cancer Genome Atlas","year":"2012","journal-title":"Nature"},{"issue":"7605","key":"10.1016\/j.humpath.2025.105826_bib3","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature17676","article-title":"Landscape of somatic mutations in 560 breast cancer whole-genome sequences","volume":"534","author":"Nik-Zainal","year":"2016","journal-title":"Nature"},{"issue":"7403","key":"10.1016\/j.humpath.2025.105826_bib4","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nature11017","article-title":"The landscape of cancer genes and mutational processes in breast cancer","volume":"486","author":"Stephens","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.humpath.2025.105826_bib5","article-title":"The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes","volume":"7","author":"Pereira","year":"2016","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.humpath.2025.105826_bib6","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J Clin Investig"},{"issue":"6","key":"10.1016\/j.humpath.2025.105826_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157368","article-title":"Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection","volume":"11","author":"Lehmann","year":"2016","journal-title":"PLoS One"},{"issue":"6797","key":"10.1016\/j.humpath.2025.105826_bib8","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.humpath.2025.105826_bib9","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1093\/annonc\/mdy024","article-title":"Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis","volume":"29","author":"Bareche","year":"2018","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.humpath.2025.105826_bib10","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.path.2021.05.009","article-title":"Molecular pathology of breast tumors: diagnostic and actionable genetic alterations","volume":"14","author":"Ross","year":"2021","journal-title":"Surg Pathol Clin"},{"issue":"1","key":"10.1016\/j.humpath.2025.105826_bib11","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/PAP.0000000000000232","article-title":"Molecular classification of breast cancer","volume":"27","author":"Tsang","year":"2020","journal-title":"Adv Anat Pathol"},{"issue":"7","key":"10.1016\/j.humpath.2025.105826_bib12","doi-asserted-by":"crossref","first-page":"499","DOI":"10.21037\/atm.2020.03.194","article-title":"Molecular subtypes and precision treatment of triple-negative breast cancer","volume":"8","author":"Zhao","year":"2020","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.humpath.2025.105826_bib13","series-title":"Breast tumours","article-title":"WHO classification of tumours","year":"2019"},{"issue":"2","key":"10.1016\/j.humpath.2025.105826_bib14","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/path.2407","article-title":"Refinement of breast cancer classification by molecular characterization of histological special types","volume":"216","author":"Weigelt","year":"2008","journal-title":"J Pathol"},{"issue":"22","key":"10.1016\/j.humpath.2025.105826_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15225491","article-title":"Lobular carcinoma of the breast: a comprehensive review with translational insights","volume":"15","author":"Batra","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.humpath.2025.105826_bib16","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.humpath.2020.06.002","article-title":"E-cadherin immunohistochemical expression in invasive lobular carcinoma of the breast: correlation with morphology and CDH1 somatic alterations","volume":"102","author":"Grabenstetter","year":"2020","journal-title":"Hum Pathol"},{"issue":"1","key":"10.1016\/j.humpath.2025.105826_bib17","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41698-024-00508-x","article-title":"Genomic and epigenomic basis of breast invasive lobular carcinomas lacking CDH1 genetic alterations","volume":"8","author":"Dopeso","year":"2024","journal-title":"npj Precis Oncol"},{"issue":"20","key":"10.1016\/j.humpath.2025.105826_bib18","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1158\/0008-5472.CAN-24-1322","article-title":"A genomics-driven artificial intelligence-based model Classifies breast invasive lobular carcinoma and discovers CDH1 inactivating mechanisms","volume":"84","author":"Pareja","year":"2024","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.humpath.2025.105826_bib19","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.cell.2015.09.033","article-title":"Comprehensive molecular portraits of invasive lobular breast cancer","volume":"163","author":"Ciriello","year":"2015","journal-title":"Cell"},{"issue":"16","key":"10.1016\/j.humpath.2025.105826_bib20","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1200\/JCO.2015.64.0334","article-title":"Genomic characterization of primary invasive lobular breast cancer","volume":"34","author":"Desmedt","year":"2016","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.humpath.2025.105826_bib21","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41523-023-00554-x","article-title":"Rare subtypes of triple negative breast cancer: current understanding and future directions","volume":"9","author":"Thomas","year":"2023","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"10.1016\/j.humpath.2025.105826_bib22","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13058-020-01324-4","article-title":"Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets","volume":"22","author":"Kurozumi","year":"2020","journal-title":"Breast Cancer Res"},{"issue":"3","key":"10.1016\/j.humpath.2025.105826_bib23","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ccell.2018.08.008","article-title":"The genomic landscape of endocrine-resistant advanced breast cancers","volume":"34","author":"Razavi","year":"2018","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.humpath.2025.105826_bib24","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41588-018-0287-5","article-title":"Acquired HER2 mutations in ER(+) metastatic breast cancer confer resistance to estrogen receptor-directed therapies","volume":"51","author":"Nayar","year":"2019","journal-title":"Nat Genet"},{"issue":"3","key":"10.1016\/j.humpath.2025.105826_bib25","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.ccell.2020.03.003","article-title":"Pan-cancer landscape and analysis of ERBB2 mutations identifies poziotinib as a clinically active inhibitor and enhancer of T-DM1 activity","volume":"37","author":"Robichaux","year":"2020","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.humpath.2025.105826_bib26","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1158\/2159-8290.CD-12-0349","article-title":"Activating HER2 mutations in HER2 gene amplification negative breast cancer","volume":"3","author":"Bose","year":"2013","journal-title":"Cancer Discov"},{"issue":"3","key":"10.1016\/j.humpath.2025.105826_bib27","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/s41591-024-03462-0","article-title":"Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial","volume":"31","author":"Okines","year":"2025","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.humpath.2025.105826_bib28","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.annonc.2023.08.003","article-title":"Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial","volume":"34","author":"Jhaveri","year":"2023","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.humpath.2025.105826_bib29","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1158\/2159-8290.CD-19-0966","article-title":"Efficacy and determinants of response to HER kinase inhibition in HER2-mutant metastatic breast cancer","volume":"10","author":"Smyth","year":"2020","journal-title":"Cancer Discov"},{"issue":"8","key":"10.1016\/j.humpath.2025.105826_bib30","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.ccell.2021.06.001","article-title":"Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2\/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity","volume":"39","author":"Hanker","year":"2021","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.humpath.2025.105826_bib31","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1038\/s41379-020-0459-6","article-title":"Genomic profiling of pleomorphic and florid lobular carcinoma in situ reveals highly recurrent ERBB2 and ERRB3 alterations","volume":"33","author":"Harrison","year":"2020","journal-title":"Mod Pathol"},{"issue":"6","key":"10.1016\/j.humpath.2025.105826_bib32","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41379-019-0449-8","article-title":"Genetic analysis of pleomorphic and florid lobular carcinoma in situ variants: frequent ERBB2\/ERBB3 alterations and clonal relationship to classic lobular carcinoma in situ and invasive lobular carcinoma","volume":"33","author":"Shamir","year":"2020","journal-title":"Mod Pathol"},{"issue":"7","key":"10.1016\/j.humpath.2025.105826_bib33","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1038\/s41379-021-00742-9","article-title":"Triple-negative breast lobular carcinoma: a luminal androgen receptor carcinoma with specific ESRRA mutations","volume":"34","author":"Bergeron","year":"2021","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.humpath.2025.105826_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11010074","article-title":"High frequency of ERBB2 activating mutations in invasive lobular breast carcinoma with pleomorphic features","volume":"11","author":"Rosa-Rosa","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.humpath.2025.105826_bib35","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/s41379-022-01084-w","article-title":"Invasive lobular carcinoma with extracellular mucin (ILCEM): clinicopathologic and molecular characterization of a rare entity","volume":"35","author":"Soong","year":"2022","journal-title":"Mod Pathol"},{"issue":"3","key":"10.1016\/j.humpath.2025.105826_bib36","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s10549-007-9809-z","article-title":"A retrospective review with long term follow up of 11,400 cases of pure mucinous breast carcinoma","volume":"111","author":"Di Saverio","year":"2008","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.humpath.2025.105826_bib37","doi-asserted-by":"crossref","first-page":"9478","DOI":"10.1038\/s41598-021-89099-2","article-title":"The genomic landscape of carcinomas with mucinous differentiation","volume":"11","author":"Nguyen","year":"2021","journal-title":"Sci Rep"},{"issue":"7","key":"10.1016\/j.humpath.2025.105826_bib38","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/jnci\/djz023","article-title":"Genomic, transcriptomic, epigenetic, and immune profiling of mucinous breast cancer","volume":"111","author":"Nguyen","year":"2019","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"10.1016\/j.humpath.2025.105826_bib39","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/jnci\/djy216","article-title":"The genomic landscape of mucinous breast cancer","volume":"111","author":"Pareja","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.humpath.2025.105826_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.anndiagpath.2024.152396","article-title":"Poor response of HER2-positive mucinous carcinomas of breast to neoadjuvant HER2-targeted therapy: a study of four cases","volume":"74","author":"Han","year":"2025","journal-title":"Ann Diagn Pathol"},{"issue":"2","key":"10.1016\/j.humpath.2025.105826_bib41","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s10549-016-3682-6","article-title":"Clinically advanced and metastatic pure mucinous carcinoma of the breast: a comprehensive genomic profiling study","volume":"155","author":"Ross","year":"2016","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"10.1016\/j.humpath.2025.105826_bib42","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/path.2368","article-title":"Genomic and immunophenotypical characterization of pure micropapillary carcinomas of the breast","volume":"215","author":"Marchio","year":"2008","journal-title":"J Pathol"},{"issue":"1","key":"10.1016\/j.humpath.2025.105826_bib43","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10549-016-3718-y","article-title":"Whole exome sequencing of rare aggressive breast cancer histologies","volume":"156","author":"Dieci","year":"2016","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.humpath.2025.105826_bib44","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/s41467-021-27794-4","article-title":"Genomic alterations and evolution of cell clusters in metastatic invasive micropapillary carcinoma of the breast","volume":"13","author":"Shi","year":"2022","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.humpath.2025.105826_bib45","doi-asserted-by":"crossref","first-page":"R46","DOI":"10.1186\/bcr3653","article-title":"Polarity gene alterations in pure invasive micropapillary carcinomas of the breast","volume":"16","author":"Gruel","year":"2014","journal-title":"Breast Cancer Res"},{"issue":"1","key":"10.1016\/j.humpath.2025.105826_bib46","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/modpathol.2017.107","article-title":"Comprehensive clinical and molecular analyses of neuroendocrine carcinomas of the breast","volume":"31","author":"Lavigne","year":"2018","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.humpath.2025.105826_bib47","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41389-022-00427-1","article-title":"Comparison of the mutational profiles of neuroendocrine breast tumours, invasive ductal carcinomas and pancreatic neuroendocrine carcinomas","volume":"11","author":"Karihtala","year":"2022","journal-title":"Oncogenesis"},{"issue":"3","key":"10.1016\/j.humpath.2025.105826_bib48","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/path.4837","article-title":"The genetic landscape of breast carcinomas with neuroendocrine differentiation","volume":"241","author":"Marchio","year":"2017","journal-title":"J Pathol"},{"issue":"1","key":"10.1016\/j.humpath.2025.105826_bib49","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1136\/jclinpath-2020-207052","article-title":"Neuroendocrine tumours of the breast: a genomic comparison with mucinous breast cancers and neuroendocrine tumours of other anatomic sites","volume":"75","author":"Pareja","year":"2022","journal-title":"J Clin Pathol"},{"issue":"10","key":"10.1016\/j.humpath.2025.105826_bib50","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1038\/s41379-022-01090-y","article-title":"Genetic and immunohistochemical profiling of small cell and large cell neuroendocrine carcinomas of the breast","volume":"35","author":"Bean","year":"2022","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.humpath.2025.105826_bib51","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s10549-016-3867-z","article-title":"Genomic landscape of small cell carcinoma of the breast contrasted to small cell carcinoma of the lung","volume":"158","author":"McCullar","year":"2016","journal-title":"Breast Cancer Res Treat"},{"issue":"7563","key":"10.1016\/j.humpath.2025.105826_bib52","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature14664","article-title":"Comprehensive genomic profiles of small cell lung cancer","volume":"524","author":"George","year":"2015","journal-title":"Nature"},{"issue":"14","key":"10.1016\/j.humpath.2025.105826_bib53","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1158\/1078-0432.CCR-15-2946","article-title":"Next-generation sequencing of pulmonary large cell neuroendocrine carcinoma reveals small cell carcinoma-like and non-small cell carcinoma-like subsets","volume":"22","author":"Rekhtman","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.humpath.2025.105826_bib54","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1097\/PAS.0000000000000671","article-title":"Pure apocrine carcinomas represent a clinicopathologically distinct androgen receptor-positive subset of triple-negative breast cancers","volume":"40","author":"Mills","year":"2016","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"10.1016\/j.humpath.2025.105826_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100125","article-title":"Triple-negative apocrine carcinomas: toward a unified group with shared molecular features and clinical behavior","volume":"36","author":"Schwartz","year":"2023","journal-title":"Mod Pathol"},{"issue":"18","key":"10.1016\/j.humpath.2025.105826_bib56","doi-asserted-by":"crossref","first-page":"7523","DOI":"10.1002\/cam4.2634","article-title":"Prognosis in triple-negative apocrine carcinomas of the breast: a population-based study","volume":"8","author":"Wu","year":"2019","journal-title":"Cancer Med"},{"issue":"15","key":"10.1016\/j.humpath.2025.105826_bib57","doi-asserted-by":"crossref","first-page":"24579","DOI":"10.18632\/oncotarget.15597","article-title":"Dose invasive apocrine adenocarcinoma has worse prognosis than invasive ductal carcinoma of breast: evidence from SEER database","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.humpath.2025.105826_bib58","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1038\/s41379-020-0589-x","article-title":"Invasive apocrine carcinoma of the breast: clinicopathologic features and comprehensive genomic profiling of 18 pure triple-negative apocrine carcinomas","volume":"33","author":"Sun","year":"2020","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.humpath.2025.105826_bib59","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41523-022-00415-z","article-title":"Clinical-pathologic characteristics and response to neoadjuvant chemotherapy in triple-negative low Ki-67 proliferation (TNLP) breast cancers","volume":"8","author":"Srivastava","year":"2022","journal-title":"NPJ Breast Cancer"},{"issue":"5","key":"10.1016\/j.humpath.2025.105826_bib60","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/modpathol.2016.39","article-title":"Genetic alterations of triple negative breast cancer by targeted next-generation sequencing and correlation with tumor morphology","volume":"29","author":"Weisman","year":"2016","journal-title":"Mod Pathol"},{"issue":"4","key":"10.1016\/j.humpath.2025.105826_bib61","doi-asserted-by":"crossref","DOI":"10.1186\/bcr2626","article-title":"Molecular apocrine differentiation is a common feature of breast cancer in patients with germline PTEN mutations","volume":"12","author":"Banneau","year":"2010","journal-title":"Breast Cancer Res"},{"issue":"9","key":"10.1016\/j.humpath.2025.105826_bib62","first-page":"1078","article-title":"Metaplastic breast carcinoma. Rare form of mammary cancer","volume":"73","author":"Huvos","year":"1973","journal-title":"N Y State J Med"},{"issue":"16","key":"10.1016\/j.humpath.2025.105826_bib63","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1158\/1078-0432.CCR-17-0108","article-title":"Whole-exome sequencing of metaplastic breast carcinoma indicates monoclonality with associated ductal carcinoma component","volume":"23","author":"Avigdor","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.humpath.2025.105826_bib64","first-page":"354","article-title":"Identical clonality of both components of mammary carcinosarcoma with differential loss of heterozygosity","volume":"10","author":"Zhuang","year":"1997","journal-title":"Mod Pathol"},{"issue":"11","key":"10.1016\/j.humpath.2025.105826_bib65","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1038\/s41379-018-0081-z","article-title":"Genomic profiling of metaplastic breast carcinomas reveals genetic heterogeneity and relationship to ductal carcinoma","volume":"31","author":"Krings","year":"2018","journal-title":"Mod Pathol: An Official Journal of the United States and Canadian Academy of Pathology, Inc."},{"issue":"5","key":"10.1016\/j.humpath.2025.105826_bib66","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.clbc.2017.04.009","article-title":"Metaplastic carcinoma of the breast is more aggressive than triple-negative breast cancer: a study from a single institution and review of literature","volume":"17","author":"El Zein","year":"2017","journal-title":"Clin Breast Cancer"},{"issue":"5","key":"10.1016\/j.humpath.2025.105826_bib67","doi-asserted-by":"crossref","first-page":"e691","DOI":"10.1016\/j.clbc.2022.01.006","article-title":"Neoadjuvant chemotherapy for metaplastic breast cancer: response rates, management, and outcomes","volume":"22","author":"Haque","year":"2022","journal-title":"Clin Breast Cancer"},{"issue":"6","key":"10.1016\/j.humpath.2025.105826_bib68","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.7150\/jca.40817","article-title":"Outcomes after treatment of metaplastic versus other breast cancer subtypes","volume":"11","author":"Moreno","year":"2020","journal-title":"J Cancer"},{"issue":"1","key":"10.1016\/j.humpath.2025.105826_bib69","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41523-021-00302-z","article-title":"Poor response to neoadjuvant chemotherapy in metaplastic breast carcinoma","volume":"7","author":"Wong","year":"2021","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"10.1016\/j.humpath.2025.105826_bib70","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/his.12861","article-title":"Breast lesions of uncertain malignant nature and limited metastatic potential: proposals to improve their recognition and clinical management","volume":"68","author":"Rakha","year":"2016","journal-title":"Histopathology (Oxf)"},{"issue":"3","key":"10.1016\/j.humpath.2025.105826_bib71","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/modpathol.2014.142","article-title":"Metaplastic breast carcinomas display genomic and transcriptomic heterogeneity [corrected]","volume":"28","author":"Weigelt","year":"2015","journal-title":"Mod Pathol"},{"issue":"14","key":"10.1016\/j.humpath.2025.105826_bib72","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.1158\/1078-0432.CCR-16-2857","article-title":"The landscape of somatic genetic alterations in metaplastic breast carcinomas","volume":"23","author":"Ng","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2025.105826_bib73","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41523-017-0048-0","article-title":"Genomic and transcriptomic heterogeneity in metaplastic carcinomas of the breast","volume":"3","author":"Piscuoglio","year":"2017","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"10.1016\/j.humpath.2025.105826_bib74","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41523-021-00250-8","article-title":"TERT promoter hotspot mutations and gene amplification in metaplastic breast cancer","volume":"7","author":"da Silva","year":"2021","journal-title":"NPJ Breast Cancer"},{"issue":"2","key":"10.1016\/j.humpath.2025.105826_bib75","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/path.5184","article-title":"Phenotypic and molecular dissection of metaplastic breast cancer and the prognostic implications","volume":"247","author":"McCart Reed","year":"2019","journal-title":"J Pathol"},{"issue":"5","key":"10.1016\/j.humpath.2025.105826_bib76","doi-asserted-by":"crossref","first-page":"642","DOI":"10.5858\/arpa.2014-0200-OA","article-title":"Genomic profiling of advanced-stage, metaplastic breast carcinoma by next-generation sequencing reveals frequent, targetable genomic abnormalities and potential new treatment options","volume":"139","author":"Ross","year":"2015","journal-title":"Arch Pathol Lab Med"},{"issue":"5","key":"10.1016\/j.humpath.2025.105826_bib77","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"issue":"3","key":"10.1016\/j.humpath.2025.105826_bib78","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s12282-017-0825-5","article-title":"TERT promoter hotspot mutations in breast cancer","volume":"25","author":"Shimoi","year":"2018","journal-title":"Breast Cancer"},{"issue":"269","key":"10.1016\/j.humpath.2025.105826_bib79","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"},{"issue":"4","key":"10.1016\/j.humpath.2025.105826_bib80","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1001\/jamaoncol.2016.5281","article-title":"Targeting the PI3K\/AKT\/mTOR pathway for the treatment of mesenchymal triple-negative breast cancer: evidence from a phase 1 trial of mTOR inhibition in combination with liposomal doxorubicin and bevacizumab","volume":"3","author":"Basho","year":"2017","journal-title":"JAMA Oncol"},{"issue":"11","key":"10.1016\/j.humpath.2025.105826_bib81","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1634\/theoncologist.2017-0498","article-title":"Comparative effectiveness of an mTOR-based systemic therapy regimen in advanced, metaplastic and nonmetaplastic triple-negative breast cancer","volume":"23","author":"Basho","year":"2018","journal-title":"Oncologist"},{"issue":"7","key":"10.1016\/j.humpath.2025.105826_bib82","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/annonc\/mdv163","article-title":"Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer","volume":"26","author":"Moulder","year":"2015","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.humpath.2025.105826_bib83","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1136\/jclinpath-2014-202824","article-title":"Low-grade fibromatosis-like spindle cell carcinomas of the breast are molecularly exiguous","volume":"68","author":"Takano","year":"2015","journal-title":"J Clin Pathol"},{"issue":"12","key":"10.1016\/j.humpath.2025.105826_bib84","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.5858\/arpa.2022-0159-OA","article-title":"TERT promoter mutation c.-124C>T commonly occurs in low-grade fibromatosis-like metaplastic breast carcinoma","volume":"147","author":"Webersinke","year":"2023","journal-title":"Arch Pathol Lab Med"},{"issue":"7","key":"10.1016\/j.humpath.2025.105826_bib85","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1136\/jclinpath-2020-207071","article-title":"High frequency of PIK3CA and TERT promoter mutations in fibromatosis-like spindle cell carcinomas","volume":"75","author":"Zhong","year":"2022","journal-title":"J Clin Pathol"},{"issue":"2","key":"10.1016\/j.humpath.2025.105826_bib86","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/his.13514","article-title":"High rate of PIK3CA mutations but no TP53 mutations in low-grade adenosquamous carcinoma of the breast","volume":"73","author":"Bataillon","year":"2018","journal-title":"Histopathology (Oxf)"},{"issue":"6","key":"10.1016\/j.humpath.2025.105826_bib87","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1053\/j.semdp.2024.10.003","article-title":"Salivary gland-like tumors of the breast: histopathologic and genetic features with clinical implications","volume":"41","author":"Schwartz","year":"2024","journal-title":"Semin Diagn Pathol"},{"key":"10.1016\/j.humpath.2025.105826_bib88","article-title":"Clinical practice guidelines in oncology","volume":"4","year":"2024","journal-title":"Breast Cancer"},{"issue":"1","key":"10.1016\/j.humpath.2025.105826_bib89","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00428-005-0084-2","article-title":"Polymorphous adenocarcinoma of the breast. Report of three cases","volume":"448","author":"Asioli","year":"2006","journal-title":"Virchows Arch: An International Journal of Pathology"},{"issue":"2","key":"10.1016\/j.humpath.2025.105826_bib90","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/tbj.13623","article-title":"Polymorphous adenocarcinoma of the breast-an exceptionally rare entity: clinicopathological description of a case and brief review","volume":"26","author":"Trihia","year":"2020","journal-title":"Breast J"},{"issue":"8","key":"10.1016\/j.humpath.2025.105826_bib91","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10081970","article-title":"Chromosome translocations, gene fusions, and their molecular consequences in pleomorphic salivary gland adenomas","volume":"10","author":"Stenman","year":"2022","journal-title":"Biomedicines"},{"issue":"2","key":"10.1016\/j.humpath.2025.105826_bib92","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00428-023-03731-2","article-title":"Molecular pathology in diagnosis and prognostication of head and neck tumors","volume":"484","author":"Skalova","year":"2024","journal-title":"Virchows Arch"},{"key":"10.1016\/j.humpath.2025.105826_bib93","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41523-020-0164-0","article-title":"Pleomorphic adenomas and mucoepidermoid carcinomas of the breast are underpinned by fusion genes","volume":"6","author":"Pareja","year":"2020","journal-title":"NPJ Breast Cancer"},{"issue":"6","key":"10.1016\/j.humpath.2025.105826_bib94","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1111\/his.14461","article-title":"Some pleomorphic adenomas of the breast share PLAG1 rearrangements with the analogous tumour of the salivary glands","volume":"79","author":"Ma","year":"2021","journal-title":"Histopathology (Oxf)"},{"issue":"4","key":"10.1016\/j.humpath.2025.105826_bib95","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/his.14380","article-title":"Adenomyoepithelioma of the breast: a proposal for classification","volume":"79","author":"Rakha","year":"2021","journal-title":"Histopathology (Oxf)"},{"issue":"1","key":"10.1016\/j.humpath.2025.105826_bib96","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1038\/s41467-018-04128-5","article-title":"Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas","volume":"9","author":"Geyer","year":"2018","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.humpath.2025.105826_bib97","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1097\/PAS.0000000000001275","article-title":"Adenomyoepitheliomas of the breast frequently harbor recurrent hotspot mutations in PIK3-AKT pathway-related genes and a subset show genetic similarity to salivary gland epithelial-myoepithelial carcinoma","volume":"43","author":"Lubin","year":"2019","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"10.1016\/j.humpath.2025.105826_bib98","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1177\/1066896918821182","article-title":"Mammary epithelial-myoepithelial carcinoma: report of a case with HRAS and PIK3CA mutations by next-generation sequencing","volume":"27","author":"Baum","year":"2019","journal-title":"Int J Surg Pathol"},{"issue":"1","key":"10.1016\/j.humpath.2025.105826_bib99","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13045-021-01158-3","article-title":"HRAS is a therapeutic target in malignant chemo-resistant adenomyoepithelioma of the breast","volume":"14","author":"Bieche","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"9","key":"10.1016\/j.humpath.2025.105826_bib100","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1038\/s41379-020-0552-x","article-title":"Adenomyoepithelial tumors of the breast: molecular underpinnings of a rare entity","volume":"33","author":"Ginter","year":"2020","journal-title":"Mod Pathol"},{"issue":"6","key":"10.1016\/j.humpath.2025.105826_bib101","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/his.14057","article-title":"Immunohistochemical assessment of HRAS Q61R mutations in breast adenomyoepitheliomas","volume":"76","author":"Pareja","year":"2020","journal-title":"Histopathology (Oxf)"},{"issue":"1","key":"10.1016\/j.humpath.2025.105826_bib102","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/PAS.0000000000000933","article-title":"Epithelial-myoepithelial carcinoma: frequent morphologic and molecular evidence of preexisting pleomorphic adenoma, common HRAS mutations in PLAG1-intact and HMGA2-intact cases, and occasional TP53, FBXW7, and SMARCB1 alterations in high-grade cases","volume":"42","author":"El Hallani","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2025.105826_bib103","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41523-018-0101-7","article-title":"Assessment of HMGA2 and PLAG1 rearrangements in breast adenomyoepitheliomas","volume":"5","author":"Pareja","year":"2019","journal-title":"NPJ Breast Cancer"},{"issue":"5","key":"10.1016\/j.humpath.2025.105826_bib104","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1001\/jama.1966.03100050096033","article-title":"Breast carcinoma in children","volume":"195","author":"McDivitt","year":"1966","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.humpath.2025.105826_bib105","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/his.13879","article-title":"Secretory carcinoma of the breast: clinicopathologic profile of 14 cases emphasising distant metastatic potential","volume":"75","author":"Hoda","year":"2019","journal-title":"Histopathology (Oxf)"},{"issue":"8","key":"10.1016\/j.humpath.2025.105826_bib106","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/modpathol.2017.32","article-title":"Genomic profiling of breast secretory carcinomas reveals distinct genetics from other breast cancers and similarity to mammary analog secretory carcinomas","volume":"30","author":"Krings","year":"2017","journal-title":"Mod Pathol"},{"issue":"24","key":"10.1016\/j.humpath.2025.105826_bib107","first-page":"8909","article-title":"The chimeric protein tyrosine kinase ETV6-NTRK3 requires both Ras-Erk1\/2 and PI3-kinase-Akt signaling for fibroblast transformation","volume":"61","author":"Tognon","year":"2001","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.humpath.2025.105826_bib108","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S1535-6108(02)00180-0","article-title":"Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma","volume":"2","author":"Tognon","year":"2002","journal-title":"Cancer Cell"},{"issue":"12","key":"10.1016\/j.humpath.2025.105826_bib109","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1097\/PAS.0000000000001366","article-title":"Pan-TRK immunohistochemistry: a useful diagnostic adjunct for secretory carcinoma of the breast","volume":"43","author":"Harrison","year":"2019","journal-title":"Am J Surg Pathol"},{"issue":"11","key":"10.1016\/j.humpath.2025.105826_bib110","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1097\/PAS.0000000000000911","article-title":"Pan-trk immunohistochemistry is an efficient and reliable screen for the detection of NTRK fusions","volume":"41","author":"Hechtman","year":"2017","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.humpath.2025.105826_bib111","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13000-022-01284-7","article-title":"Clinicopathological features and genomic profiles of a group of secretory breast carcinomas in which progressive cases have more complex genomic features","volume":"17","author":"Lei","year":"2022","journal-title":"Diagn Pathol"},{"issue":"8","key":"10.1016\/j.humpath.2025.105826_bib112","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2025.105826_bib113","article-title":"Successful targeted therapy of refractory pediatric ETV6-NTRK3 fusion-positive secretory breast carcinoma","volume":"2017","author":"Shukla","year":"2017","journal-title":"JCO Precis Oncol"},{"issue":"4","key":"10.1016\/j.humpath.2025.105826_bib114","doi-asserted-by":"crossref","DOI":"10.1186\/bcr2613","article-title":"Adenoid cystic carcinoma of the breast in the United States (1977 to 2006): a population-based cohort study","volume":"12","author":"Ghabach","year":"2010","journal-title":"Breast Cancer Res"},{"issue":"2","key":"10.1016\/j.humpath.2025.105826_bib115","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/PAS.0000000000001378","article-title":"Predictors of outcome in mammary adenoid cystic carcinoma: a multi-institutional study","volume":"44","author":"Slodkowska","year":"2020","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1016\/j.humpath.2025.105826_bib116","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/ng.3502","article-title":"An oncogenic MYB feedback loop drives alternate cell fates in adenoid cystic carcinoma","volume":"48","author":"Drier","year":"2016","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.humpath.2025.105826_bib117","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/path.4573","article-title":"Genomic landscape of adenoid cystic carcinoma of the breast","volume":"237","author":"Martelotto","year":"2015","journal-title":"J Pathol"},{"issue":"44","key":"10.1016\/j.humpath.2025.105826_bib118","doi-asserted-by":"crossref","first-page":"18740","DOI":"10.1073\/pnas.0909114106","article-title":"Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck","volume":"106","author":"Persson","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.humpath.2025.105826_bib119","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/path.5006","article-title":"MYBL1 rearrangements and MYB amplification in breast adenoid cystic carcinomas lacking the MYB-NFIB fusion gene","volume":"244","author":"Kim","year":"2018","journal-title":"J Pathol"},{"issue":"7","key":"10.1016\/j.humpath.2025.105826_bib120","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1097\/PAS.0000000000000878","article-title":"MYB labeling by immunohistochemistry is more sensitive and specific for breast adenoid cystic carcinoma than MYB labeling by FISH","volume":"41","author":"Poling","year":"2017","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"10.1016\/j.humpath.2025.105826_bib121","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/s41379-021-00931-6","article-title":"The clinical behavior and genomic features of the so-called adenoid cystic carcinomas of the solid variant with basaloid features","volume":"35","author":"Schwartz","year":"2022","journal-title":"Mod Pathol"},{"issue":"7","key":"10.1016\/j.humpath.2025.105826_bib122","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1097\/PAS.0000000000001913","article-title":"MYB RNA in situ hybridization is a useful diagnostic tool to distinguish breast adenoid cystic carcinoma from other triple-negative breast carcinomas","volume":"46","author":"Butcher","year":"2022","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.humpath.2025.105826_bib123","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/path.2974","article-title":"Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple-negative and basal-like breast cancers","volume":"226","author":"Wetterskog","year":"2012","journal-title":"J Pathol"},{"issue":"4","key":"10.1016\/j.humpath.2025.105826_bib124","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/00000478-200204000-00002","article-title":"Solid variant of mammary adenoid cystic carcinoma with basaloid features: a study of nine cases","volume":"26","author":"Shin","year":"2002","journal-title":"Am J Surg Pathol"},{"issue":"12","key":"10.1016\/j.humpath.2025.105826_bib125","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100324","article-title":"Solid-basaloid adenoid cystic carcinoma of the breast: an aggressive subtype enriched for notch pathway and chromatin modifier mutations with MYB overexpression","volume":"36","author":"Shamir","year":"2023","journal-title":"Mod Pathol: An Official Journal of the United States and Canadian Academy of Pathology, Inc."},{"issue":"6","key":"10.1016\/j.humpath.2025.105826_bib126","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/s41379-019-0425-3","article-title":"Solid-type adenoid cystic carcinoma of the breast, a distinct molecular entity enriched in NOTCH and CREBBP mutations","volume":"33","author":"Masse","year":"2020","journal-title":"Mod Pathol"},{"issue":"3","key":"10.1016\/j.humpath.2025.105826_bib127","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/his.15276","article-title":"MYB expression by immunohistochemistry is highly specific and sensitive for detection of solid variant of adenoid cystic carcinoma of the breast among all triple-negative breast cancers","volume":"85","author":"Batra","year":"2024","journal-title":"Histopathology (Oxf)"},{"key":"10.1016\/j.humpath.2025.105826_bib128","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1146\/annurev-pathol-052016-100127","article-title":"The varied roles of notch in cancer","volume":"12","author":"Aster","year":"2017","journal-title":"Annu Rev Pathol"},{"issue":"2","key":"10.1016\/j.humpath.2025.105826_bib129","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s10637-019-00739-x","article-title":"Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma","volume":"38","author":"Even","year":"2020","journal-title":"Invest N Drugs"},{"issue":"3","key":"10.1016\/j.humpath.2025.105826_bib130","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1200\/JCO.2016.67.5264","article-title":"Activating NOTCH1 mutations define a distinct subgroup of patients with adenoid cystic carcinoma who have poor prognosis, propensity to bone and liver metastasis, and potential responsiveness to Notch1 inhibitors","volume":"35","author":"Ferrarotto","year":"2017","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.humpath.2025.105826_bib131","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70663","article-title":"Clinical outcomes with notch inhibitors in notch-activated recurrent\/metastatic adenoid cystic carcinoma","volume":"14","author":"Hoff","year":"2025","journal-title":"Cancer Med"},{"issue":"11","key":"10.1016\/j.humpath.2025.105826_bib132","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1038\/modpathol.2016.134","article-title":"Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer","volume":"29","author":"Fusco","year":"2016","journal-title":"Mod Pathol"},{"issue":"4","key":"10.1016\/j.humpath.2025.105826_bib133","first-page":"196","article-title":"Low-grade mucoepidermoid carcinoma of the breast","volume":"103","author":"Patchefsky","year":"1979","journal-title":"Arch Pathol Lab Med"},{"issue":"12","key":"10.1016\/j.humpath.2025.105826_bib134","first-page":"3192","article-title":"Breast mucoepidermoid carcinoma: a case report and review of literature","volume":"13","author":"Ye","year":"2020","journal-title":"Int J Clin Exp Pathol"},{"issue":"3","key":"10.1016\/j.humpath.2025.105826_bib135","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/his.13779","article-title":"CRTC1-MAML2 fusion in mucoepidermoid carcinoma of the breast","volume":"74","author":"Bean","year":"2019","journal-title":"Histopathology (Oxf)"},{"issue":"10","key":"10.1016\/j.humpath.2025.105826_bib136","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100270","article-title":"Genetic and immunohistochemical profiling of mammary hidradenoma and comparison to mucoepidermoid carcinoma","volume":"36","author":"Black","year":"2023","journal-title":"Mod Pathol"},{"issue":"6","key":"10.1016\/j.humpath.2025.105826_bib137","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.humpath.2008.11.004","article-title":"Mucoepidermoid carcinoma of the breast shares cytogenetic abnormality with mucoepidermoid carcinoma of the salivary gland: a case report with molecular analysis and review of the literature","volume":"40","author":"Camelo-Piragua","year":"2009","journal-title":"Hum Pathol"},{"issue":"6","key":"10.1016\/j.humpath.2025.105826_bib138","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/gcc.20440","article-title":"Frequent fusion of the CRTC1 and MAML2 genes in clear cell variants of cutaneous hidradenomas","volume":"46","author":"Winnes","year":"2007","journal-title":"Genes Chromosomes Cancer"},{"issue":"7","key":"10.1016\/j.humpath.2025.105826_bib139","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2025.100756","article-title":"RNA in situ hybridization detection of CRTC1\/3::MAML2 fusions and LINC00473 in mucoepidermoid carcinomas and hidradenomas of breast, salivary glands, and skin","volume":"38","author":"Rutland","year":"2025","journal-title":"Mod Pathol"},{"issue":"5","key":"10.1016\/j.humpath.2025.105826_bib140","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/ajcp\/100.5.507","article-title":"Carcinoma of the breast arising in microglandular adenosis","volume":"100","author":"James","year":"1993","journal-title":"Am J Clin Pathol"},{"issue":"4","key":"10.1016\/j.humpath.2025.105826_bib141","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/00000478-198604000-00002","article-title":"Is microglandular adenosis a precancerous disease? A study of carcinoma arising therein","volume":"10","author":"Rosenblum","year":"1986","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.humpath.2025.105826_bib142","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/modpathol.2016.161","article-title":"Genetic analysis of microglandular adenosis and acinic cell carcinomas of the breast provides evidence for the existence of a low-grade triple-negative breast neoplasia family","volume":"30","author":"Geyer","year":"2017","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2025.105826_bib143","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.breast.2022.10.012","article-title":"Acinic cell carcinoma of the breast: a comprehensive review","volume":"66","author":"Ajkunic","year":"2022","journal-title":"Breast (Edinb)"},{"issue":"2","key":"10.1016\/j.humpath.2025.105826_bib144","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/path.4566","article-title":"The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesis-generating study","volume":"237","author":"Guerini-Rocco","year":"2015","journal-title":"J Pathol"},{"issue":"6","key":"10.1016\/j.humpath.2025.105826_bib145","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100144","article-title":"NR4A3 expression is consistently absent in acinic cell carcinomas of the breast: a potential nosologic shift","volume":"36","author":"Richardson","year":"2023","journal-title":"Mod Pathol"},{"issue":"4","key":"10.1016\/j.humpath.2025.105826_bib146","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/ajcp\/aqx016","article-title":"Breast tumor resembling tall cell variant of papillary thyroid carcinoma: a solid papillary neoplasm with characteristic immunohistochemical profile and few recurrent mutations","volume":"147","author":"Bhargava","year":"2017","journal-title":"Am J Clin Pathol"},{"issue":"24","key":"10.1016\/j.humpath.2025.105826_bib147","doi-asserted-by":"crossref","first-page":"7118","DOI":"10.1158\/0008-5472.CAN-16-0298","article-title":"IDH2 mutations define a unique subtype of breast cancer with altered nuclear polarity","volume":"76","author":"Chiang","year":"2016","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.humpath.2025.105826_bib148","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1097\/00000478-200308000-00008","article-title":"Breast tumor resembling the tall cell variant of papillary thyroid carcinoma: report of 5 cases","volume":"27","author":"Eusebi","year":"2003","journal-title":"Am J Surg Pathol"},{"issue":"7","key":"10.1016\/j.humpath.2025.105826_bib149","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1097\/PAS.0000000000000853","article-title":"Solid papillary breast carcinomas resembling the tall cell variant of papillary thyroid neoplasms: a unique invasive tumor with indolent behavior","volume":"41","author":"Foschini","year":"2017","journal-title":"Am J Surg Pathol"},{"issue":"23","key":"10.1016\/j.humpath.2025.105826_bib150","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1158\/0008-5472.CAN-23-0816","article-title":"Analysis and visualization of longitudinal genomic and clinical data from the AACR project GENIE biopharma collaborative in cBioPortal","volume":"83","author":"de Bruijn","year":"2023","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.humpath.2025.105826_bib151","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/PAS.0000000000002004","article-title":"Recurrent IDH2 mutations in salivary gland striated duct adenoma define an expanded histologic spectrum distinct from canalicular adenoma","volume":"47","author":"Rooper","year":"2023","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2025.105826_bib152","article-title":"Solid-papillary carcinoma with reverse polarity (SPCRP) harboring a novel IDH1 R132C mutation: a case confirming the expected IDH1\/IDH2 dichotomy","volume":"21","author":"Weisman","year":"2020","journal-title":"Hum Pathol: Case Reports"},{"issue":"9","key":"10.1016\/j.humpath.2025.105826_bib153","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/s41379-018-0047-1","article-title":"Solid papillary carcinoma with reverse polarity of the breast harbors specific morphologic, immunohistochemical and molecular profile in comparison with other benign or malignant papillary lesions of the breast: a comparative study of 9 additional cases","volume":"31","author":"Alsadoun","year":"2018","journal-title":"Mod Pathol"},{"issue":"6","key":"10.1016\/j.humpath.2025.105826_bib154","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/s41379-019-0442-2","article-title":"Immunohistochemical analysis of IDH2 R172 hotspot mutations in breast papillary neoplasms: applications in the diagnosis of tall cell carcinoma with reverse polarity","volume":"33","author":"Pareja","year":"2020","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.humpath.2025.105826_bib155","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s13402-011-0010-3","article-title":"Pathology of hereditary breast cancer","volume":"34","author":"van der Groep","year":"2011","journal-title":"Cell Oncol"},{"issue":"1","key":"10.1016\/j.humpath.2025.105826_bib156","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/his.14808","article-title":"Hereditary breast cancer: syndromes, tumour pathology and molecular testing","volume":"82","author":"Sokolova","year":"2023","journal-title":"Histopathology (Oxf)"},{"issue":"23","key":"10.1016\/j.humpath.2025.105826_bib157","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.humpath.2025.105826_bib158","article-title":"Homologous recombination deficiency landscape of breast cancers and real-world effectiveness of poly ADP-ribose polymerase inhibitors in patients with somatic BRCA1\/2, germline PALB2, or homologous recombination deficiency signature","volume":"7","author":"Batalini","year":"2023","journal-title":"JCO Precis Oncol"},{"issue":"7","key":"10.1016\/j.humpath.2025.105826_bib159","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1093\/annonc\/mdz132","article-title":"Whole-genome sequencing reveals clinically relevant insights into the aetiology of familial breast cancers","volume":"30","author":"Nones","year":"2019","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.humpath.2025.105826_bib160","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1158\/1055-9965.EPI-11-0775","article-title":"Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1\/2 (CIMBA)","volume":"21","author":"Mavaddat","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.humpath.2025.105826_bib161","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.humpath.2018.10.005","article-title":"Subtypes in BRCA-mutated breast cancer","volume":"84","author":"Sonderstrup","year":"2019","journal-title":"Hum Pathol"},{"issue":"1","key":"10.1016\/j.humpath.2025.105826_bib162","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12920-019-0545-0","article-title":"Comprehensive genomic characterization of breast tumors with BRCA1 and BRCA2 mutations","volume":"12","author":"Lal","year":"2019","journal-title":"BMC Med Genom"},{"issue":"1","key":"10.1016\/j.humpath.2025.105826_bib163","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41523-023-00561-y","article-title":"Genomic analysis of advanced breast cancer tumors from talazoparib-treated gBRCA1\/2mut carriers in the ABRAZO study","volume":"9","author":"Turner","year":"2023","journal-title":"NPJ Breast Cancer"},{"issue":"17","key":"10.1016\/j.humpath.2025.105826_bib164","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14174157","article-title":"Homologous recombination deficiency scar: mutations and beyond-implications for precision oncology","volume":"14","author":"van der Wiel","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"7463","key":"10.1016\/j.humpath.2025.105826_bib165","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.humpath.2025.105826_bib166","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nrc.2015.21","article-title":"BRCAness revisited","volume":"16","author":"Lord","year":"2016","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"10.1016\/j.humpath.2025.105826_bib167","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.humpath.2025.105826_bib168","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.humpath.2025.105826_bib169","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.humpath.2025.105826_bib170","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1200\/JCO.20.00299","article-title":"Management of hereditary breast cancer: American society of clinical oncology, American society for radiation oncology, and society of surgical oncology guideline","volume":"38","author":"Tung","year":"2020","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.humpath.2025.105826_bib171","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1200\/JCO.21.01532","article-title":"Adjuvant PARP inhibitors in patients with high-risk early-stage HER2-negative breast cancer and germline BRCA mutations: ASCO hereditary breast cancer guideline rapid recommendation update","volume":"39","author":"Tung","year":"2021","journal-title":"J Clin Oncol"},{"issue":"36","key":"10.1016\/j.humpath.2025.105826_bib172","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1200\/JCO.20.02151","article-title":"Tbcrc 048: phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes","volume":"38","author":"Tung","year":"2020","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.humpath.2025.105826_bib173","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nm.4292","article-title":"HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures","volume":"23","author":"Davies","year":"2017","journal-title":"Nat Med"},{"issue":"21","key":"10.1016\/j.humpath.2025.105826_bib174","doi-asserted-by":"crossref","first-page":"4714","DOI":"10.1158\/1078-0432.CCR-22-0749","article-title":"Mutational signature 3 detected from clinical panel sequencing is associated with responses to olaparib in breast and ovarian cancers","volume":"28","author":"Batalini","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.humpath.2025.105826_bib175","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/ng.3037","article-title":"Exome sequencing identifies highly recurrent MED12 somatic mutations in breast fibroadenoma","volume":"46","author":"Lim","year":"2014","journal-title":"Nat Genet"},{"issue":"6053","key":"10.1016\/j.humpath.2025.105826_bib176","first-page":"252","article-title":"MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas","volume":"334","author":"Makinen","year":"2011","journal-title":"Sci Technol Humanit"},{"issue":"4","key":"10.1016\/j.humpath.2025.105826_bib177","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/path.5333","article-title":"Genomic characterisation of breast fibroepithelial lesions in an international cohort","volume":"249","author":"Md Nasir","year":"2019","journal-title":"J Pathol"},{"issue":"4","key":"10.1016\/j.humpath.2025.105826_bib178","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1158\/1541-7786.MCR-14-0578","article-title":"Next-gen sequencing exposes frequent MED12 mutations and actionable therapeutic targets in phyllodes tumors","volume":"13","author":"Cani","year":"2015","journal-title":"Mol Cancer Res"},{"issue":"4","key":"10.1016\/j.humpath.2025.105826_bib179","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/path.4672","article-title":"Massively parallel sequencing of phyllodes tumours of the breast reveals actionable mutations, and TERT promoter hotspot mutations and TERT gene amplification as likely drivers of progression","volume":"238","author":"Piscuoglio","year":"2016","journal-title":"J Pathol"},{"issue":"11","key":"10.1016\/j.humpath.2025.105826_bib180","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/ng.3409","article-title":"Genomic landscapes of breast fibroepithelial tumors","volume":"47","author":"Tan","year":"2015","journal-title":"Nat Genet"},{"issue":"10","key":"10.1016\/j.humpath.2025.105826_bib181","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/bjc.2015.116","article-title":"Frequent MED12 mutations in phyllodes tumours of the breast","volume":"112","author":"Yoshida","year":"2015","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.humpath.2025.105826_bib182","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/cncr.32672","article-title":"The emerging role of mediator complex subunit 12 in tumorigenesis and response to chemotherapeutics","volume":"126","author":"Zhang","year":"2020","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.humpath.2025.105826_bib183","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s12920-019-0588-2","article-title":"A novel genomic panel as an adjunctive diagnostic tool for the characterization and profiling of breast Fibroepithelial lesions","volume":"12","author":"Sim","year":"2019","journal-title":"BMC Med Genom"},{"key":"10.1016\/j.humpath.2025.105826_bib184","doi-asserted-by":"crossref","DOI":"10.1111\/his.15455","article-title":"Malignant phyllodes tumours of the breast: the case for revising WHO's 'full house' diagnostic criteria","author":"Tan","year":"2025","journal-title":"Histopathology (Oxf)"},{"issue":"8","key":"10.1016\/j.humpath.2025.105826_bib185","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1038\/bjc.2015.326","article-title":"TERT promoter mutations are frequent and show association with MED12 mutations in phyllodes tumors of the breast","volume":"113","author":"Yoshida","year":"2015","journal-title":"Br J Cancer"},{"issue":"9","key":"10.1016\/j.humpath.2025.105826_bib186","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1038\/modpathol.2016.97","article-title":"Genomic profiling of malignant phyllodes tumors reveals aberrations in FGFR1 and PI-3 kinase\/RAS signaling pathways and provides insights into intratumoral heterogeneity","volume":"29","author":"Liu","year":"2016","journal-title":"Mod Pathol"},{"issue":"12","key":"10.1016\/j.humpath.2025.105826_bib187","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1093\/oncolo\/oyae218","article-title":"Genomic landscape of malignant phyllodes tumors reveals multiple targetable opportunities","volume":"29","author":"Rosenberger","year":"2024","journal-title":"Oncologist"},{"issue":"12","key":"10.1016\/j.humpath.2025.105826_bib188","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2024.100593","article-title":"Targeted DNA sequencing in diagnosis of malignant phyllodes tumors with emphasis on tumors with keratin and p63 expression","volume":"37","author":"Ye","year":"2024","journal-title":"Mod Pathol"},{"issue":"7","key":"10.1016\/j.humpath.2025.105826_bib189","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1111\/his.12898","article-title":"Liposarcomatous differentiation in malignant phyllodes tumours is unassociated with MDM2 or CDK4 amplification","volume":"68","author":"Lyle","year":"2016","journal-title":"Histopathology (Oxf)"},{"issue":"12","key":"10.1016\/j.humpath.2025.105826_bib190","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1097\/PAS.0000000000000301","article-title":"A subset of malignant phyllodes tumors express p63 and p40: a diagnostic pitfall in breast core needle biopsies","volume":"38","author":"Cimino-Mathews","year":"2014","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"10.1016\/j.humpath.2025.105826_bib191","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s10549-018-5067-5","article-title":"Genomic profile of breast sarcomas: a comparison with malignant phyllodes tumours","volume":"174","author":"Lim","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.humpath.2025.105826_bib192","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/his.12865","article-title":"An approach to the diagnosis of spindle cell lesions of the breast","volume":"68","author":"Rakha","year":"2016","journal-title":"Histopathology (Oxf)"},{"issue":"12","key":"10.1016\/j.humpath.2025.105826_bib193","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1097\/PAS.0b013e318176dbc7","article-title":"Primary angiosarcoma of the breast: clinicopathologic analysis of 49 cases, suggesting that grade is not prognostic","volume":"32","author":"Nascimento","year":"2008","journal-title":"Am J Surg Pathol"},{"issue":"12","key":"10.1016\/j.humpath.2025.105826_bib194","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1002\/cncr.21531","article-title":"Angiosarcoma of the breast","volume":"104","author":"Vorburger","year":"2005","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.humpath.2025.105826_bib195","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/PAS.0000000000001998","article-title":"Histopathologic grading is of prognostic significance in primary angiosarcoma of breast: proposal of a simplified 2-tier grading system","volume":"47","author":"Kuba","year":"2023","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"10.1016\/j.humpath.2025.105826_bib196","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1097\/01.pas.0000126055.33916.0b","article-title":"Cutaneous angiosarcoma following breast-conserving surgery and radiation: an analysis of 27 cases","volume":"28","author":"Billings","year":"2004","journal-title":"Am J Surg Pathol"},{"issue":"8","key":"10.1016\/j.humpath.2025.105826_bib197","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1038\/s41379-020-0511-6","article-title":"Primary mammary angiosarcomas harbor frequent mutations in KDR and PIK3CA and show evidence of distinct pathogenesis","volume":"33","author":"Beca","year":"2020","journal-title":"Mod Pathol"},{"issue":"4","key":"10.1016\/j.humpath.2025.105826_bib198","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/ng.2921","article-title":"Recurrent PTPRB and PLCG1 mutations in angiosarcoma","volume":"46","author":"Behjati","year":"2014","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.humpath.2025.105826_bib199","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41591-019-0749-z","article-title":"The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research","volume":"26","author":"Painter","year":"2020","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.humpath.2025.105826_bib200","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/his.14458","article-title":"The genetics of vascular tumours: an update","volume":"80","author":"Torrence","year":"2022","journal-title":"Histopathology (Oxf)"},{"issue":"2","key":"10.1016\/j.humpath.2025.105826_bib201","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/tbj.12380","article-title":"Refractory angiosarcoma of the breast with VEGFR2 upregulation successfully treated with sunitinib","volume":"21","author":"Silva","year":"2015","journal-title":"Breast J"},{"issue":"1","key":"10.1016\/j.humpath.2025.105826_bib202","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1186\/s12885-018-4523-2","article-title":"Apatinib treatment for KIT- and KDR-amplified angiosarcoma: a case report","volume":"18","author":"Yang","year":"2018","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.humpath.2025.105826_bib203","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mds237","article-title":"An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas","volume":"24","author":"Agulnik","year":"2013","journal-title":"Ann Oncol: Official Journal of the European Society for Medical Oncology"},{"issue":"19","key":"10.1016\/j.humpath.2025.105826_bib204","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1200\/JCO.2008.20.4495","article-title":"Phase II study of sorafenib in patients with metastatic or recurrent sarcomas","volume":"27","author":"Maki","year":"2009","journal-title":"J Clin Oncol: Official Journal of the American Society of Clinical Oncology"},{"issue":"19","key":"10.1016\/j.humpath.2025.105826_bib205","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1002\/cncr.34403","article-title":"OER-073: a multicenter phase 2 study evaluating the role of pazopanib in angiosarcoma","volume":"128","author":"Thiebaud","year":"2022","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.humpath.2025.105826_bib206","doi-asserted-by":"crossref","DOI":"10.1101\/mcs.a004408","article-title":"Dramatic response of metastatic cutaneous angiosarcoma to an immune checkpoint inhibitor in a patient with xeroderma pigmentosum: whole-genome sequencing aids treatment decision in end-stage disease","volume":"5","author":"Momen","year":"2019","journal-title":"Cold Spring Harb Mol Case Stud"},{"issue":"1","key":"10.1016\/j.humpath.2025.105826_bib207","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/gcc.20827","article-title":"Consistent MYC and FLT4 gene amplification in radiation-induced angiosarcoma but not in other radiation-associated atypical vascular lesions","volume":"50","author":"Guo","year":"2011","journal-title":"Gene Chromosome Cancer"},{"issue":"1","key":"10.1016\/j.humpath.2025.105826_bib208","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2353\/ajpath.2010.090637","article-title":"MYC high level gene amplification is a distinctive feature of angiosarcomas after irradiation or chronic lymphedema","volume":"176","author":"Manner","year":"2010","journal-title":"Am J Pathol"},{"issue":"1","key":"10.1016\/j.humpath.2025.105826_bib209","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/modpathol.2011.134","volume":"25","author":"Mentzel","year":"2012","journal-title":"Mod Pathol"},{"issue":"10","key":"10.1016\/j.humpath.2025.105826_bib210","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/gcc.22272","article-title":"Near universal detection of alterations in CTNNB1 and Wnt pathway regulators in desmoid-type fibromatosis by whole-exome sequencing and genomic analysis","volume":"54","author":"Crago","year":"2015","journal-title":"Gene Chromosome Cancer"},{"issue":"9","key":"10.1016\/j.humpath.2025.105826_bib211","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1097\/PAS.0000000000001517","article-title":"Lower rate of CTNNB1 mutations and higher rate of APC mutations in desmoid fibromatosis of the breast: a series of 134 tumors","volume":"44","author":"Norkowski","year":"2020","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"10.1016\/j.humpath.2025.105826_bib212","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/j.1365-2559.2007.02794.x","article-title":"Immunohistochemistry for beta-catenin in the differential diagnosis of spindle cell lesions: analysis of a series and review of the literature","volume":"51","author":"Carlson","year":"2007","journal-title":"Histopathology (Oxf)"},{"issue":"11","key":"10.1016\/j.humpath.2025.105826_bib213","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1038\/modpathol.2010.141","article-title":"beta-catenin\/Wnt signalling pathway in fibromatosis, metaplastic carcinomas and phyllodes tumours of the breast","volume":"23","author":"Lacroix-Triki","year":"2010","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2025.105826_bib214","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ejca.2019.11.013","article-title":"The management of desmoid tumours: a joint global consensus-based guideline approach for adult and paediatric patients","volume":"127","author":"Desmoid Tumor","year":"2020","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.humpath.2025.105826_bib215","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.breast.2004.09.014","article-title":"A case of nodular fascitis of the breast and review of the literature","volume":"14","author":"Brown","year":"2005","journal-title":"Breast (Edinb)"},{"issue":"10","key":"10.1016\/j.humpath.2025.105826_bib216","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1038\/s41379-021-00844-4","article-title":"Nodular fasciitis of the breast: clinicopathologic and molecular characterization with identification of novel USP6 fusion partners","volume":"34","author":"Cloutier","year":"2021","journal-title":"Mod Pathol"},{"issue":"4","key":"10.1016\/j.humpath.2025.105826_bib217","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1159\/000448185","article-title":"Breast nodular fasciitis: a comprehensive review","volume":"11","author":"Paliogiannis","year":"2016","journal-title":"Breast Care"},{"key":"10.1016\/j.humpath.2025.105826_bib218","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2015-213076","article-title":"A spontaneously resolving breast lesion: imaging and cytological findings of nodular fasciitis of the breast with FISH showing USP6 gene rearrangement","volume":"2015","author":"Kang","year":"2015","journal-title":"BMJ Case Rep"},{"issue":"11","key":"10.1016\/j.humpath.2025.105826_bib219","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1038\/modpathol.2017.78","article-title":"USP6 activation in nodular fasciitis by promoter-swapping gene fusions","volume":"30","author":"Patel","year":"2017","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.humpath.2025.105826_bib220","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/ng0197-95","article-title":"Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma","volume":"15","author":"Simon","year":"1997","journal-title":"Nat Genet"},{"issue":"23","key":"10.1016\/j.humpath.2025.105826_bib221","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1038\/sj.onc.1204426","article-title":"Structural and functional analysis of a chimeric protein COL1A1-PDGFB generated by the translocation t(17;22)(q22;q13.1) in Dermatofibrosarcoma protuberans (DP)","volume":"20","author":"Simon","year":"2001","journal-title":"Oncogene"},{"issue":"11","key":"10.1016\/j.humpath.2025.105826_bib222","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1038\/s41379-018-0089-4","article-title":"Alternative PDGFD rearrangements in dermatofibrosarcomas protuberans without PDGFB fusions","volume":"31","author":"Dadone-Montaudie","year":"2018","journal-title":"Mod Pathol"},{"issue":"9","key":"10.1016\/j.humpath.2025.105826_bib223","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/gcc.22663","article-title":"Dermatofibrosarcoma protuberans with a novel COL6A3-PDGFD fusion gene and apparent predilection for breast","volume":"57","author":"Dickson","year":"2018","journal-title":"Gene Chromosome Cancer"},{"issue":"4","key":"10.1016\/j.humpath.2025.105826_bib224","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jid.2020.06.039","article-title":"A multicenter phase II study of pazopanib in patients with unresectable dermatofibrosarcoma protuberans","volume":"141","author":"Delyon","year":"2021","journal-title":"J Invest Dermatol"},{"issue":"4","key":"10.1016\/j.humpath.2025.105826_bib225","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1158\/1078-0432.CCR-15-1243","article-title":"Efficacy and biological activity of imatinib in metastatic dermatofibrosarcoma protuberans (DFSP)","volume":"22","author":"Stacchiotti","year":"2016","journal-title":"Clin Cancer Res"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817725001133?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817725001133?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T01:02:14Z","timestamp":1756170134000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817725001133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":225,"alternative-id":["S0046817725001133"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2025.105826","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetic landscapes of breast tumors by next-generation sequencing with focus on less common types and genotype-phenotype correlations","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2025.105826","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"105826"}}